CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 358 enrolled
Drug / intervention
Infliximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00725543
NCT00725543N/ACompleted
CompareCT.gov

Remicade Therapy in Ankylosing Spondylitis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions

Merck Sharp & Dohme LLC·observational·Posted Jul 30, 2008·Updated Sep 30, 2015

In Brief

An observational study evaluating Infliximab for Spondylitis, Ankylosing. Completed, enrolled 358 participants.

Detailed Summary

This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time span of Remicade between infusions for ankylosing spondylitis (AS).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSpondylitis, Ankylosing
Countries--
CollaboratorsCentocor, Inc.

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2008
Enrollment StartJun 1, 2004
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 17.9 years ago

Interventions

Infliximabbiological

Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.